Compare Two Anti-Scorpion Venom Serum In Children
Launched by LABORATORIOS DE BIOLOGICOS Y REACTIVOS DE MÉXICO, S.A. DE C.V. · Aug 11, 2011
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
We consider relevant conduct this study because the poisoning scorpion bite represents a public health problem.
This is a randomized clinical trial, which included 120 subjects of both sexes aged 0 and 15 years old and residents of the state of Guanajuato, divided into 2 groups: 60 patients received antiscorpion serum of Birmex and 60 patients receive other commercial serum (Alacramyn).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Scorpion sting
- • 2. Either sex
- • 3. Age 1 to 15 years
- • 4. Signing an informed consent (signed by parent or guardian)
- • 5. Being residents of the state of Guanajuato
- Exclusion Criteria:
- • 1. Previous treatment with gamma globulin or immunoglobulin
- • 2. Blood transfusion at any stage of life
- • 3. Patients treated with drugs that interact with anti-scorpion serum
- • 4. History or history of sensitivity or intolerance to anti-scorpion serum or horse products
- • 5. Pregnancy
- • 6. Any immunodeficiency
- • 7. Patients who have participated in a research protocol in the previous month.
About Laboratorios De Biologicos Y Reactivos De México, S.A. De C.V.
Laboratorios de Biológicos y Reactivos de México, S.A. de C.V. is a leading pharmaceutical company dedicated to the development and production of high-quality biopharmaceuticals and diagnostic reagents. With a strong commitment to innovation and excellence, the organization focuses on advancing healthcare solutions that meet the needs of patients and healthcare providers. Leveraging state-of-the-art technology and rigorous quality control measures, the company ensures the safety and efficacy of its products while actively participating in clinical trials to further enhance medical knowledge and therapeutic options. Through collaboration with healthcare professionals and research institutions, Laboratorios de Biológicos y Reactivos de México aims to contribute significantly to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
León, Guanajuato, Mexico
Patients applied
Trial Officials
Ma. Eugenia Jimenez-Corona, PhD
Principal Investigator
Laboratorios de Biologicos y Reactivos de México SA de CV
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials